Discover five promising Prader-Willi syndrome therapies climbing the clinical ladder and nearing FDA approval in the coming ...

See more on the latest on Soleno Therapeutics (SLNO) stock after VYKAT XR approval. Learn why post-approval commercialization ...

Soleno Therapeutics (NASDAQ:SLNO) saw its stock climb 14% following news that Acadia Pharmaceuticals’ (NASDAQ:ACAD) Phase 3 trial for a Prader-Willi syndrome therapy failed to meet its primary ...

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients ...

Soleno Therapeutics is breathing easier with a report from Acadia Pharmaceuticals that its candidate to treat hyperphagia in patients with Prader-Willi Syndrome (PWS) has come up short in a phase 3 ...

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. ACADIA Pharmaceuticals Inc. stands second among them. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a ...

SGLT2 inhibitors significantly improved glycaemic control and reduced the albumin-to-creatinine ratio without affecting body weight in patients with Prader-Willi syndrome and type 2 diabetes (T2D); ...

We recently published 10 Stocks Crushing Wall Street, AI Stocks Dominate. Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the top performers on Tuesday. Soleno Therapeutics extended its winning ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ...

(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday said it plans to start a Phase 2 study of TNX-2900 for the treatment of Prader-Willi syndrome, a genetic disorder that affects multiple ...